Log in
NASDAQ:CGEN

Compugen Stock Forecast, Price & News

$18.86
+0.70 (+3.85 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$17.80
Now: $18.86
$18.91
50-Day Range
$14.41
MA: $16.70
$19.45
52-Week Range
$3.83
Now: $18.86
$19.90
Volume1.91 million shs
Average Volume1.28 million shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.73
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Read More
Compugen logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.02 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.80 million
Book Value$0.75 per share

Profitability

Net Income$-27,340,000.00

Miscellaneous

Employees89
Market Cap$1.29 billion
Next Earnings Date11/9/2020 (Estimated)
OptionableOptionable
$18.86
+0.70 (+3.85 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Compugen (NASDAQ:CGEN) Frequently Asked Questions

How has Compugen's stock price been impacted by Coronavirus?

Compugen's stock was trading at $11.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CGEN shares have increased by 59.4% and is now trading at $18.86.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Compugen?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Compugen
.

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for Compugen
.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02.
View Compugen's earnings history
.

What price target have analysts set for CGEN?

8 Wall Street analysts have issued 1 year target prices for Compugen's shares. Their forecasts range from $13.00 to $28.00. On average, they expect Compugen's stock price to reach $19.75 in the next year. This suggests a possible upside of 4.7% from the stock's current price.
View analysts' price targets for Compugen
.

Are investors shorting Compugen?

Compugen saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 6,910,000 shares, an increase of 12.7% from the August 15th total of 6,130,000 shares. Based on an average daily volume of 1,450,000 shares, the days-to-cover ratio is presently 4.8 days.
View Compugen's Short Interest
.

Who are some of Compugen's key competitors?

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Gilead Sciences (GILD), Netflix (NFLX) and Vertex Pharmaceuticals (VRTX).

Who are Compugen's key executives?

Compugen's management team includes the following people:
  • Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)
  • Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)
  • Dr. John J. Hunter Ph.D., Chief Scientific Officer (Age 56)
  • Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)
  • Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 51)

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Macquarie Group Ltd. (0.85%), Taylor Frigon Capital Management LLC (0.74%), Rothschild Investment Corp IL (0.50%), Defender Capital LLC. (0.31%), Phoenix Holdings Ltd. (0.29%) and Swiss National Bank (0.25%).

Which institutional investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Verition Fund Management LLC, Taylor Frigon Capital Management LLC, Defender Capital LLC., Raymond James & Associates, Glenmede Trust Co. NA, and Rothschild Investment Corp IL.

Which institutional investors are buying Compugen stock?

CGEN stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Swiss National Bank, Atom Investors LP, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Aigen Investment Management LP, PDT Partners LLC, and Goldman Sachs Group Inc..

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $18.86.

How big of a company is Compugen?

Compugen has a market capitalization of $1.29 billion and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe.

What is Compugen's official website?

The official website for Compugen is www.cgen.com.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.